Projects per year
Abstract
Antibody-mediated cell depletion therapy has proven to provide significant clinical benefit in treatment of lymphomas and leukemias, driving the development of improved therapies with novel mechanisms of cell killing. A current clinical target for B-cell lymphoma is CD22, a B-cell-specific member of the sialic acid binding Ig-like lectin (siglec) family that recognizes alpha 2-6-linked sialylated glycans as ligands. Here, we describe a novel approach for targeting B lymphoma cells with doxorubicin-loaded liposomal nanoparticles displaying high-affinity glycan ligands of CD22. The targeted liposomes are actively bound and endocytosed by CD22 on B cells, and significantly extend life in a xenograft model of human B-cell lymphoma. Moreover, they bind and kill malignant B cells from peripheral blood samples obtained from patients with hairy cell leukemia, marginal zone lymphoma, and chronic lymphocytic leukemia. The results demonstrate the potential for using a carbohydrate recognition-based approach for efficiently targeting B cells in vivo that can offer improved treatment options for patients with B-cell malignancies. (Blood. 2010;115(23):4778-4786)
Original language | English |
---|---|
Pages (from-to) | 4778-4786 |
Number of pages | 9 |
Journal | Blood |
Volume | 115 |
Issue number | 23 |
Early online date | 24 Feb 2010 |
DOIs | |
Publication status | Published - 10 Jun 2010 |
Keywords
- Pegylated liposomal doxorubicin
- Non-Hodgkins lymphoma
- Drug delivery
- Inotuzumzb ozogamicin
- Cytotoxic activity
- Flow cytometry
- CIS ligands
- Sialoadhesin
- Chemotherapy
- Efficacy
Fingerprint
Dive into the research topics of 'In vivo targeting of B-cell lymphoma with glycan ligands of CD22'. Together they form a unique fingerprint.Projects
- 1 Finished
-
Aref#d: 19149. Role of Siglecs in Disease (Senior Research Fellowship)
Crocker, P. (Investigator)
1/11/07 → 30/04/13
Project: Research